Skip to main content
Equibles

COHANCE · Cohance Lifesciences Limited

Use COHANCE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COHANCE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
458.55 INR -13.00 (-2.76%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 33.93K Avg daily vol (3M) 146.33K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close458.55 INR Open471.55 INR Day456.15–475.95 INR 52W close279.75–629.50 INR Avg vol 30d56K Last earningsNov 6, 2026 DataSep 2020–Nov 2026

Raw chart and full-history price indicators begin at the captured split on Sep 25, 2020; bars on opposite sides are not compared.

Latest documents

2026
Nov 6
Earnings call
Revenue rises 13% sequentially, adjusted EBITDA reaches 458 million

Cohance reported revenue increasing 13% sequentially to 4767 million and adjusted EBITDA of 458 million, with margin improving to 10%. Management expects HALF 2 of FY27 year-on-year revenue and EBITDA growth, while assessing the Surya Paik closure order.

4 source passages
Revenue increased 13% sequentially to 4767 million. While adjusted EBITDA increased to 458 million, with the adjusted EBITDA margin improving to 10%. Based on the visibility we have today, we continue to expect HALF 2 of FY27 to deliver year-on-year growth on both revenue and EBITDA. At this stage, we are also assessing any further impact from the Surya Paik closure order. At Cohance, right, we have a good relation with several large pharmaceutical customers Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲39.7% 3.07B INR 828.80M INR '25 Q3 · 4.02B INR 420.10M INR '25 Q4 ▲138.1% 5.49B INR 488.81M INR '26 Q1 ▲115.6% 5.56B INR 740.80M INR '26 Q2 ▲77.3% 5.45B INR 367.20M INR '26 Q3 ▲54% 6.19B INR 195.50M INR '26 Q4 ▼23.1% 4.22B INR −241.20M INR '27 Q1 LATEST ▼14.2% 4.77B INR 152.20M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 279.75 INR Now 458.55 INR · 51% Range high 629.50 INR
vs 200-day avg +12% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

Raw-price comparisons begin at the captured split on Sep 25, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
XBOM:COHANCE +5.8% -0.1% +9.6% +3.2% -13.2%

Exchange listing

Market
XBOM
Ticker
COHANCE
ISIN
INE03QK01018
Security
Ordinary share
Trading currency
INR

Company

Website
https://cohance.com/
Investor relations
https://www.cohance.com/financial-info

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2022-09-09 6.00 INR
2022-05-13 2.00 INR
2022-02-15 3.00 INR
2021-08-13 1.00 INR
2021-02-17 1.00 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-06 Audio Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-08-05 Audio Transcript
    Earnings Call
  • Earnings call · Q4 2026 2026-05-12 Audio Transcript
    Earnings Call for the Quarter Ended March 31, 2026